Compare HTHT & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTHT | MEDP |
|---|---|---|
| Founded | 2005 | 1992 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 15.4B |
| IPO Year | 2010 | 2016 |
| Metric | HTHT | MEDP |
|---|---|---|
| Price | $49.03 | $619.05 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 12 |
| Target Price | $56.60 | ★ $473.17 |
| AVG Volume (30 Days) | ★ 1.6M | 242.8K |
| Earning Date | 05-19-2026 | 04-22-2026 |
| Dividend Yield | ★ 4.07% | N/A |
| EPS Growth | N/A | ★ 20.98 |
| EPS | N/A | ★ 8.53 |
| Revenue | N/A | N/A |
| Revenue This Year | $7.18 | $13.19 |
| Revenue Next Year | $6.71 | $7.75 |
| P/E Ratio | ★ $30.34 | $71.99 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $35.69 | $373.00 |
| 52 Week High | $56.53 | $677.90 |
| Indicator | HTHT | MEDP |
|---|---|---|
| Relative Strength Index (RSI) | 69.82 | 62.91 |
| Support Level | $47.34 | $567.90 |
| Resistance Level | $50.62 | $627.59 |
| Average True Range (ATR) | 1.29 | 16.85 |
| MACD | 0.71 | -0.19 |
| Stochastic Oscillator | 96.59 | 73.84 |
H World Group Ltd a foremost, fast-growing multi-brand hotel group with international operations. The principal business activities of the Company are to develop and operate leased and owned, manachised and franchised hotels mainly in the PRC or PRC Mainland. The Group has two operating segments which are legacy Huazhu and legacy DH according to the way management intends to evaluate results and allocate resources within the Group. The majority of revenue comes from legacy Huazhu. The company has presence in Greater China and also Outside Greater China.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.